Literature DB >> 16952738

Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis.

Edward V Loftus1.   

Abstract

Patients with UC are at increased risk of CRC, but a series of population-based studies published within the past 5 years suggest that this risk has decreased over time. The crude annual incidence rate of CRC in UC ranges from approximately 1 in 500 to 1 in 1600. In some cohorts, an elevated risk of CRC relative to the general population can no longer be demonstrated. The exact mechanism for this decrease in risk remains unclear but may be attributable to a combination of more widespread use of maintenance therapy and surveillance colonoscopy as well as more judicious reliance on colectomy. In addition to the classic risk factors of increased extent and duration of UC, it seems that PSC, a family history of sporadic CRC, severity of histologic bowel inflammation, and young age at colitis onset are independent risk factors for cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16952738     DOI: 10.1016/j.gtc.2006.07.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  28 in total

1.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

2.  New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

Authors:  Charles A Sninsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

3.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

Review 4.  Cancer in inflammatory bowel disease: lessons from animal models.

Authors:  Daniel A Sussman; Rebeca Santaolalla; Sebastian Strobel; Rishu Dheer; Maria T Abreu
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

Review 5.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 6.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

7.  Colorectal cancer in inflammatory bowel disease.

Authors:  Jonathan Potack; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2008-09-30       Impact factor: 4.519

8.  Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-17       Impact factor: 11.382

Review 9.  Novel diagnostic and therapeutic techniques for surveillance of dysplasia in patients with inflammatory bowel disease.

Authors:  Marietta Iacucci; T Uraoka; M Fort Gasia; N Yahagi
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

Review 10.  Epidemiology and management options for colorectal cancer in children.

Authors:  Raya Saab; Wayne L Furman
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.